Sun, Sep 21, 2014, 12:53 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • starfe11 starfe11 Feb 22, 2013 9:56 AM Flag

    TREAT NMD

    huge report comparing prosensa/gsk/avi trials page 13 on

    can't post the link

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • what are the bottom line results?

    • Dr Günter Scheuerbrandt is well known for his "DMD research reports" and interviews with DMD experts which he writes in a language that is accessible to all.
      Dr Scheuerbrandt was born in 1930 in Sensburg in Germany. After studying chemistry in Freiburg and Grenoble, he spent two years as a postdoc at Harvard with Professor Konrad Bloch and in Stanford with Professor Arthur Kornberg. After returning to Germany, he worked for the German pharmaceutical company E. Merck in Darmstadt and then in the United States again, where he worked at their offices near New York as their representative for specialty chemicals and diagnostic tests until 1973.
      Dr Scheuerbrandt’s work in the US led him into the DMD screening field and on leaving Merck he set up a private laboratory in Breitnau in the Black Forest to perfect newborn screening using a bioluminescent creatine kinase (CK) test. In 1977, his lab started a routine voluntary test program for all of Germany.

      • 1 Reply to starfe11
      • In reality SRPT has released far less information than Prosensa/GSK in terms of the 6 MWT. It makes Dr Scheurbrandt's report somewhat irrelevant as a comparison IMO. Apparently he received no or little communications from the scientific of the Eteplirsen clinical trials and therefore has only what we could read. Prosensa on the other hand has release per patient information on 6 MWT and other clinical results on numerous patients. *** The FDA will insist on seeing and will see everything.

        Sentiment: Buy

 
SRPT
21.78-0.75(-3.33%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.